DermaSensor vs Glass Health
Glass Health lists Pro at $90 per month and Max at $200, while DermaSensor's FAQ describes a monthly rental under a one-year agreement with a try-and-return option and gives no outright-purchase price.
DermaSensor returns Monitor or Investigate Further on a lesion the physician already finds suspicious. Its FAQ says EHR integration is not available yet, so results go in by hand or report upload, and a dedicated CPT code has not been established. Glass offers differential diagnosis with citations and must-not-miss flags, plus billing suggestions with MDM justification. Max adds EHR workflows for Epic, eClinicalWorks, athenahealth and Elation, which the vendor calls assisted.
A primary care group with many suspicious lesions takes DermaSensor and enters results by hand. A group short on documentation time looks at Glass Pro or Max.
Decision support · Reviewed November 2, 2026
DermaSensor
by DermaSensor · founded 2009
Handheld spectroscopy device giving primary care physicians an AI score on skin lesions already judged suspicious.
Glass Health
by Glass Health · founded 2021
DDx plus literature-grounded A&P plus ambient scribe in one workflow.
When to pick each one
DermaSensor
- Monitor or Investigate Further reading on suspicious lesions
- De Novo grant DEN230008
- Monthly rental, try-and-return option
Glass Health
- Pro at $90 per month, ad-free
- Differentials with must-not-miss flags
- Billing suggestions with MDM justification
Score
Each row shows points earned of points available under the published rubric.
DermaSensor
49of 100
Glass Health
42of 100
| Dimension | DermaSensor | Glass Health | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 0 / 12 | +12 |
| HIPAA / SOC2 / BAA | 0 / 10 | 6 / 10 | -6 |
| EHR integrations (count) | 0 / 5.6 | 2.8 / 5.6 | -2.8 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4.8 | 3.4 / 4.8 | -3.4 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 8.4 / 21 | +6.3 |
| RCT / meta-analysis / systematic review | 4.5 / 9 | 0 / 9 | +4.5 |
| Funding & adoption signal | 3 / 12 | 8.4 / 12 | -5.4 |
| Pricing transparency | 1.3 / 2.5 | 2.5 / 2.5 | -1.2 |
| Years in market | 6 / 6 | 4.2 / 6 | +1.8 |
Scroll horizontally to see every column.
Pricing
DermaSensor
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No published price for an outright purchase. Monthly rental subscription, one-year device use agreement with try-and-return option. |
Glass Health
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Lite | n/a | n/a | Limited scribing and clinical decision support. Carries ad sponsorships. |
| Starter | $20 | n/a | Carries ad sponsorships. |
| Pro | $90 | n/a | Most popular tier, ad-free. |
| Max | $200 | n/a | For clinics. EHR integration (Athena, Epic, eCW, Elation) is available only on this tier. |
Evidence
DermaSensor
FDA decisions
DEN230008 (opens in new tab)De Novo2024-01-12
DermaSensor
Peer-reviewed
3 PubMed records name DermaSensor.
- Learnings from the first AI-enabled skin cancer device for primary care authorized by FDA. (opens in new tab)
- Enhancing Diagnostic Precision in Primary Care: A Multireader Multicase (MRMC) Study of an AI-Powered Handheld Elastic Scattering Spectroscopy Device for Informed Referral Decisions in Melanoma Evaluation. (opens in new tab)
- Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer. (opens in new tab)
Glass Health
FDA decisions
No FDA decision cited in our research as of October 26, 2026.
Peer-reviewed
1 PubMed record names Glass Health.
Community
1 post sourced: 0 positive, 1 neutral, 0 negative.
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | DermaSensor | Glass Health |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Epic, athenahealth, eClinicalWorks, Elation |
| Founded | 2009 | 2021 |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.